Study: Rivaroxaban is effective, but increases bleeding risk

02/8/2013 | Forbes · MedPage Today (free registration)

The anticoagulant rivaroxaban was effective at preventing venous thromboembolism in patients with acute illnesses, but it was associated with a significant increase in bleeding risk, according to a study published in the New England Journal of Medicine. The study compared rivaroxaban with enoxaparin.

View Full Article in:

Forbes · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA